Ad5.CMVTO.TIMP-3 [Ad5.CMVTO.TIMP-3] clinical trials

Participants undergoing coronary artery bypass graft will receive veins removed from legs treated with gene therapy and a placebo for grafting. Vein segments are treated at random with either gene therapy or a placebo.

This study is testing a new gene therapy to help keep leg veins open after a heart bypass operation. We're looking at its safety and the best dose. Patients will receive both the gene therapy and a dummy treatment (placebo) on different vein sections.